REPLIGEN CORP Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31)
REPLIGEN CORP (RGEN) reported Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31) of -$2.88 million for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-15.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefitContinuingOperations · last filed 2013-03-15
- REPLIGEN CORP income tax expense (benefit), continuing operations (deprecated 2013-01-31) for fiscal 2012 was -$2.88M.
| Period end | Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31) 9 month | Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31) 12 month |
|---|---|---|
| 2012-12-31 | -$2.88M 10-K · filed 2013-03-15 | |
| 2011-12-31 | $15.74K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |